Top story
FDA accepts uniQure's AMT-130 Huntington's gene therapy BLA for priority review, decision due May 2027 with adcomm planned
The FDA granted priority review and set a May 1, 2027 PDUFA date, and appears likely to convene an advisory committee for the first Huntington's disease gene therapy BLA, which rests on a small, externally controlled dataset.
ReutersFDA to review uniQure's Huntington's gene therapy, decision due on May 2027LabonlinePersonalised melanoma vaccine cuts risk of recurrenceInklHuntington's Gene Therapy AMT-130 Gets FDA Priority Review and a May 2027 Decision Date, Advisory Panel PlannedDrugdiscoverynewsGene therapy for Huntington's disease reaches FDA reviewHuntingtonsdiseasenewsFDA grants priority review to gene therapy for Huntington’sYahooUniQure gets an FDA decision date; Teva scraps brain drug studyPharmaphorumuniQure set for May FDA verdict on Huntington's gene therapyDealroomFDA accepts uniQure's Huntington's gene therapy for priority reviewNeurologyliveFDA Grants Priority Review to Huntington Disease Gene Therapy BLAFiercebiotechFDA grants uniQure’s Huntington’s gene therapy priority review, teeing up ‘defining milestone’HdbuzzFDA sets May 2027 decision date on AMT-130 gene therapy for HDGurufocusuniQure's Gene Therapy BLA for Huntington's Disease Gains FDA PrAllsciFDA grants uniQure’s Huntington’s gene therapy Priority Review on small, externally controlled datasetGenengnewsFDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene TherapyBiospaceUniQure snags May Day decision date for Huntington’s gene therapy after arduous year